Three-dose Covid-19 vaccine produces strong immune response in children ages 6 months to 5 years, Pfizer and BioNTech say

Three child-size doses of the Pfizer/BioNTech Covid-19 vaccine appeared to be safe and showed a strong immune response in children ages 6 months to 5 years, the companies said Monday. The vaccine makers said they will finish submitting the trial data to the US Food and Drug Administration this week.